{"protocolSection": {"identificationModule": {"nctId": "NCT00273052", "orgStudyIdInfo": {"id": "COR103561"}, "organization": {"fullName": "GlaxoSmithKline", "class": "INDUSTRY"}, "briefTitle": "COREG MR Versus TOPROL-XL On The Lipid Profile Of Normolipidemic Or Mildly Dyslipidemic Patients With Hypertension", "officialTitle": "A Randomized, Double-Blind, Multi-Center Study Comparing the Effects of Carvedilol Phosphate Modified Release Formulation (COREG- MR) With Metoprolol Succinate (TOPROL XL) on the Lipid Profile in Normolipidemic, or Mildly Dyslipidemic Hypertensive Patients"}, "statusModule": {"statusVerifiedDate": "2018-03", "overallStatus": "COMPLETED", "startDateStruct": {"date": "2006-01-05"}, "primaryCompletionDateStruct": {"date": "2007-12-01", "type": "ACTUAL"}, "completionDateStruct": {"date": "2007-12-28", "type": "ACTUAL"}, "studyFirstSubmitDate": "2006-01-05", "studyFirstSubmitQcDate": "2006-01-05", "studyFirstPostDateStruct": {"date": "2006-01-09", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2008-12-19", "resultsFirstSubmitQcDate": "2010-01-06", "resultsFirstPostDateStruct": {"date": "2010-02-01", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2018-03-19", "lastUpdatePostDateStruct": {"date": "2018-06-25", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "GlaxoSmithKline", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This study was designed to determine whether treatment with COREG MR is more effective at maintaining a better lipid profile than treatment with TOPROL-XL for hypertension."}, "conditionsModule": {"conditions": ["Hypertension"], "keywords": ["hypertension"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 514, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Carvedilol Phosphate modified release formulation", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Carvedilol Phosphate modified release formulation"]}, {"label": "metoprolol succinate", "type": "ACTIVE_COMPARATOR", "interventionNames": ["Drug: metoprolol succinate"]}], "interventions": [{"type": "DRUG", "name": "Carvedilol Phosphate modified release formulation", "armGroupLabels": ["Carvedilol Phosphate modified release formulation"]}, {"type": "DRUG", "name": "metoprolol succinate", "armGroupLabels": ["metoprolol succinate"], "otherNames": ["Carvedilol Phosphate modified release formulation"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Triglycerides Levels by Treatment Group at Maintenance Month 6", "description": "Blood draw for triglyceride levels. Full beta quantification test performed which uses ultracentrifugation to partially separate lipoprotein classes and is the basis for the reference methods. Change = Month 6 value minus Baseline value.", "timeFrame": "Baseline and Month 6"}, {"measure": "Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) Levels by Treatment Group at Maintenance Month 6", "description": "Blood draw for HDL-C levels. Full beta Quant test performed with HDL subclasses. Change = Month 6 value minus Baseline value.", "timeFrame": "Baseline and Month 6"}], "secondaryOutcomes": [{"measure": "Change From Baseline in Log Transformed High Sensitivity C-reactive Protein (Hs-CRP) by Treatment Group at Maintenance Month 6", "description": "Blood draw for hs-CRP. Change = Month 6 value minus Baseline value.", "timeFrame": "Baseline and Month 6"}, {"measure": "Change From Baseline in Log Transformed Lipoprotein-associated Phospholipase A2 (LpPLA2) by Treatment Group at Maintenance Month 6", "description": "Blood draw for LpPLA2 activity. Change = Month 6 value minus Baseline value.", "timeFrame": "Baseline and Month 6"}, {"measure": "Change From Baseline in Blood Pressure by Treatment Group at Maintenance Month 6", "description": "Manual physical examination (cuff blood pressure). Change = Month 6 value minus Baseline value.", "timeFrame": "Baseline and Month 6"}, {"measure": "Change From Baseline in Heart Rate by Treatment Group at Maintenance Month 6", "description": "Manual physical examination. Change = Month 6 value minus Baseline value. (BPM=beats per minute)", "timeFrame": "Baseline and Month 6"}, {"measure": "Change From Baseline in Weight by Treatment Group at Maintenance Month", "description": "Manual physical examination. Change = Month 6 value minus Baseline value.", "timeFrame": "Baseline and Month 6"}, {"measure": "Change From Baseline in Additional Lipid Parameters by Treatment Group With Unit of Measures of mg/dL at Maintenance Month 6", "description": "Blood draw for lipid levels. Full beta Quant test performed with HDL subclasses and IDL. IDL=Intermediate density lipoproteins, LDL=Low-density lipoprotein, VLDL=Very Low density lipoprotein, HDL=High-density lipoprotein. Change = Month 6 value minus Baseline value.", "timeFrame": "Baseline and Month 6"}, {"measure": "Change From Baseline in Additional Lipid Parameters by Treatment Group With Unit of Measures of g/L at Maintenance Month 6", "description": "Blood draw for lipid levels. Full beta Quant test performed. Change = Month 6 value minus Baseline value.", "timeFrame": "Baseline and Month 6"}, {"measure": "Change From Baseline in Fasting Insulin (Glycemic Parameter) by Treatment Group at Maintenance Month 6", "description": "Blood draw for glycemia levels. Full beta Quant test performed. Test for Fasting plasma glucose, HbA1c, fasting insulin. Homeostasis model Assessment (HOMA) is a computer-generated model consisting of non-linear empirical equations solved numerically to predict glucose, Insulin and C-peptide concentrations in fasting subjects for insulin sensitivity (%S). Change = Month 6 value minus Baseline value.", "timeFrame": "Baseline and Month 6"}, {"measure": "Change From Baseline in Hemoglobin A1c (HbA1c) (Glycemic Parameter) by Treatment Group at Maintenance Month 6", "description": "Blood draw for glycemia levels. Full beta Quant test performed. Test for Fasting plasma glucose, HbA1c, fasting insulin. Homeostasis model Assessment (HOMA) is a computer-generated model consisting of non-linear empirical equations solved numerically to predict glucose, Insulin and C-peptide concentrations in fasting subjects for insulin sensitivity (%S). Change = Month 6 value minus Baseline value.", "timeFrame": "Baseline and Month 6"}, {"measure": "Change From Baseline in c-Peptide (Glycemic Parameter) by Treatment Group at Maintenance Month 6", "description": "Blood draw for glycemia levels. Full beta Quant test performed. Test for Fasting plasma glucose, HbA1c, fasting insulin. Homeostasis model Assessment (HOMA) is a computer-generated model consisting of non-linear empirical equations solved numerically to predict glucose, Insulin and C-peptide concentrations in fasting subjects for insulin sensitivity (%S). Change = Month 6 value minus Baseline value.", "timeFrame": "Baseline and Month 6"}, {"measure": "Change From Baseline in Homeostasis Model Assessment (Glycemic Parameter) by Treatment Group at Maintenance Month 6", "description": "Blood draw for glycemia levels. Full beta Quant test performed. Test for Fasting plasma glucose, HbA1c, fasting insulin. Homeostasis model Assessment (HOMA) is a computer-generated model consisting of non-linear empirical equations solved numerically to predict glucose, Insulin and C-peptide concentrations in fasting subjects for insulin sensitivity (%S). Change = Month 6 value minus Baseline value.", "timeFrame": "Baseline and Month 6"}, {"measure": "Change From Baseline in Fasting Plasma Glucose (FPG) (Glycemic Parameter) by Treatment Group at Maintenance Month 6", "description": "Blood draw for glycemia levels. Full beta Quant test performed. Test for Fasting plasma glucose, HbA1c, fasting insulin. Homeostasis model Assessment (HOMA) is a computer-generated model consisting of non-linear empirical equations solved numerically to predict glucose, Insulin and C-peptide concentrations in fasting subjects for insulin sensitivity (%S). Change = Month 6 value minus Baseline value.", "timeFrame": "Baseline and Month 6"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Documented history of hypertension\n* Triglycerides of 120-400 mg/mL\n* LDLc levels not requiring lipid lowering medication.\n\nExclusion Criteria:\n\n* Has known contraindication to alpha- or beta-blocker therapy.\n* Has taken any non-ocular beta-blockers within three months before screening.\n* Has Type I or II diabetes.\n* Taking lipid lowering medications.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "80 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "GSK Clinical Trials", "affiliation": "GlaxoSmithKline", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "GSK Investigational Site", "city": "Birmingham", "state": "Alabama", "zip": "35205", "country": "United States", "geoPoint": {"lat": 33.52066, "lon": -86.80249}}, {"facility": "GSK Investigational Site", "city": "Birmingham", "state": "Alabama", "zip": "35209", "country": "United States", "geoPoint": {"lat": 33.52066, "lon": -86.80249}}, {"facility": "GSK Investigational Site", "city": "Birmingham", "state": "Alabama", "zip": "35211", "country": "United States", "geoPoint": {"lat": 33.52066, "lon": -86.80249}}, {"facility": "GSK Investigational Site", "city": "Birmingham", "state": "Alabama", "zip": "35242", "country": "United States", "geoPoint": {"lat": 33.52066, "lon": -86.80249}}, {"facility": "GSK Investigational Site", "city": "Montgomery", "state": "Alabama", "zip": "36106", "country": "United States", "geoPoint": {"lat": 32.36681, "lon": -86.29997}}, {"facility": "GSK Investigational Site", "city": "Chandler", "state": "Arizona", "zip": "85224", "country": "United States", "geoPoint": {"lat": 33.30616, "lon": -111.84125}}, {"facility": "GSK Investigational Site", "city": "Mesa", "state": "Arizona", "zip": "85201", "country": "United States", "geoPoint": {"lat": 33.42227, "lon": -111.82264}}, {"facility": "GSK Investigational Site", "city": "Phoenix", "state": "Arizona", "zip": "85014", "country": "United States", "geoPoint": {"lat": 33.44838, "lon": -112.07404}}, {"facility": "GSK Investigational Site", "city": "Phoenix", "state": "Arizona", "zip": "85029", "country": "United States", "geoPoint": {"lat": 33.44838, "lon": -112.07404}}, {"facility": "GSK Investigational Site", "city": "Tucson", "state": "Arizona", "zip": "85723", "country": "United States", "geoPoint": {"lat": 32.22174, "lon": -110.92648}}, {"facility": "GSK Investigational Site", "city": "Tucson", "state": "Arizona", "zip": "85741", "country": "United States", "geoPoint": {"lat": 32.22174, "lon": -110.92648}}, {"facility": "GSK Investigational Site", "city": "Fayetteville", "state": "Arkansas", "zip": "72701", "country": "United States", "geoPoint": {"lat": 36.06258, "lon": -94.15743}}, {"facility": "GSK Investigational Site", "city": "Little Rock", "state": "Arkansas", "zip": "72205", "country": "United States", "geoPoint": {"lat": 34.74648, "lon": -92.28959}}, {"facility": "GSK Investigational Site", "city": "Carmichael", "state": "California", "zip": "95608", "country": "United States", "geoPoint": {"lat": 38.61713, "lon": -121.32828}}, {"facility": "GSK Investigational Site", "city": "Healdsburg", "state": "California", "zip": "95448", "country": "United States", "geoPoint": {"lat": 38.61047, "lon": -122.86916}}, {"facility": "GSK Investigational Site", "city": "Irvine", "state": "California", "zip": "92618", "country": "United States", "geoPoint": {"lat": 33.66946, "lon": -117.82311}}, {"facility": "GSK Investigational Site", "city": "La Jolla", "state": "California", "zip": "92037", "country": "United States", "geoPoint": {"lat": 32.84727, "lon": -117.2742}}, {"facility": "GSK Investigational Site", "city": "Los Angeles", "state": "California", "zip": "90057", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "GSK Investigational Site", "city": "Los Angeles", "state": "California", "zip": "90502", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "GSK Investigational Site", "city": "Mission Viejo", "state": "California", "zip": "92691", "country": "United States", "geoPoint": {"lat": 33.60002, "lon": -117.672}}, {"facility": "GSK Investigational Site", "city": "Poway", "state": "California", "zip": "92064", "country": "United States", "geoPoint": {"lat": 32.96282, "lon": -117.03586}}, {"facility": "GSK Investigational Site", "city": "Sacramento", "state": "California", "zip": "95816", "country": "United States", "geoPoint": {"lat": 38.58157, "lon": -121.4944}}, {"facility": "GSK Investigational Site", "city": "San Diego", "state": "California", "zip": "92177", "country": "United States", "geoPoint": {"lat": 32.71533, "lon": -117.15726}}, {"facility": "GSK Investigational Site", "city": "Spring Valley", "state": "California", "zip": "91978", "country": "United States", "geoPoint": {"lat": 32.74477, "lon": -116.99892}}, {"facility": "GSK Investigational Site", "city": "Stockton", "state": "California", "zip": "95204", "country": "United States", "geoPoint": {"lat": 37.9577, "lon": -121.29078}}, {"facility": "GSK Investigational Site", "city": "Torrance", "state": "California", "zip": "90503", "country": "United States", "geoPoint": {"lat": 33.83585, "lon": -118.34063}}, {"facility": "GSK Investigational Site", "city": "Vista", "state": "California", "zip": "92084", "country": "United States", "geoPoint": {"lat": 33.20004, "lon": -117.24254}}, {"facility": "GSK Investigational Site", "city": "Avon", "state": "Connecticut", "zip": "06001", "country": "United States", "geoPoint": {"lat": 41.80982, "lon": -72.83065}}, {"facility": "GSK Investigational Site", "city": "Altamonte Springs", "state": "Florida", "zip": "32714", "country": "United States", "geoPoint": {"lat": 28.66111, "lon": -81.36562}}, {"facility": "GSK Investigational Site", "city": "Clearwater", "state": "Florida", "zip": "33755", "country": "United States", "geoPoint": {"lat": 27.96585, "lon": -82.8001}}, {"facility": "GSK Investigational Site", "city": "Fort Lauderdale", "state": "Florida", "zip": "33308", "country": "United States", "geoPoint": {"lat": 26.12231, "lon": -80.14338}}, {"facility": "GSK Investigational Site", "city": "Jacksonville", "state": "Florida", "zip": "32205", "country": "United States", "geoPoint": {"lat": 30.33218, "lon": -81.65565}}, {"facility": "GSK Investigational Site", "city": "Jacksonville", "state": "Florida", "zip": "32216", "country": "United States", "geoPoint": {"lat": 30.33218, "lon": -81.65565}}, {"facility": "GSK Investigational Site", "city": "Jacksonville", "state": "Florida", "zip": "32259", "country": "United States", "geoPoint": {"lat": 30.33218, "lon": -81.65565}}, {"facility": "GSK Investigational Site", "city": "Pembroke Pines", "state": "Florida", "zip": "33024", "country": "United States", "geoPoint": {"lat": 26.00315, "lon": -80.22394}}, {"facility": "GSK Investigational Site", "city": "Atlanta", "state": "Georgia", "zip": "30308", "country": "United States", "geoPoint": {"lat": 33.749, "lon": -84.38798}}, {"facility": "GSK Investigational Site", "city": "Marietta", "state": "Georgia", "zip": "30067", "country": "United States", "geoPoint": {"lat": 33.9526, "lon": -84.54993}}, {"facility": "GSK Investigational Site", "city": "Roswell", "state": "Georgia", "zip": "30076", "country": "United States", "geoPoint": {"lat": 34.02316, "lon": -84.36159}}, {"facility": "GSK Investigational Site", "city": "Aurora", "state": "Illinois", "zip": "60504", "country": "United States", "geoPoint": {"lat": 41.76058, "lon": -88.32007}}, {"facility": "GSK Investigational Site", "city": "Chicago", "state": "Illinois", "zip": "60611", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "GSK Investigational Site", "city": "Gillespie", "state": "Illinois", "zip": "62033", "country": "United States", "geoPoint": {"lat": 39.12977, "lon": -89.81954}}, {"facility": "GSK Investigational Site", "city": "Vernon Hills", "state": "Illinois", "zip": "60061", "country": "United States", "geoPoint": {"lat": 42.21947, "lon": -87.97952}}, {"facility": "GSK Investigational Site", "city": "Evansville", "state": "Indiana", "zip": "47714", "country": "United States", "geoPoint": {"lat": 37.97476, "lon": -87.55585}}, {"facility": "GSK Investigational Site", "city": "Indianapolis", "state": "Indiana", "zip": "46260", "country": "United States", "geoPoint": {"lat": 39.76838, "lon": -86.15804}}, {"facility": "GSK Investigational Site", "city": "Wichita", "state": "Kansas", "zip": "67205", "country": "United States", "geoPoint": {"lat": 37.69224, "lon": -97.33754}}, {"facility": "GSK Investigational Site", "city": "Wichita", "state": "Kansas", "zip": "67214", "country": "United States", "geoPoint": {"lat": 37.69224, "lon": -97.33754}}, {"facility": "GSK Investigational Site", "city": "Bossier City", "state": "Louisiana", "zip": "71111", "country": "United States", "geoPoint": {"lat": 32.51599, "lon": -93.73212}}, {"facility": "GSK Investigational Site", "city": "Auburn", "state": "Maine", "zip": "04210", "country": "United States", "geoPoint": {"lat": 44.09785, "lon": -70.23117}}, {"facility": "GSK Investigational Site", "city": "Natick", "state": "Massachusetts", "zip": "01760", "country": "United States", "geoPoint": {"lat": 42.28343, "lon": -71.3495}}, {"facility": "GSK Investigational Site", "city": "Taunton", "state": "Massachusetts", "zip": "02780.", "country": "United States", "geoPoint": {"lat": 41.9001, "lon": -71.08977}}, {"facility": "GSK Investigational Site", "city": "West Yarmouth", "state": "Massachusetts", "zip": "02673", "country": "United States", "geoPoint": {"lat": 41.65011, "lon": -70.24113}}, {"facility": "GSK Investigational Site", "city": "Detroit", "state": "Michigan", "zip": "48235", "country": "United States", "geoPoint": {"lat": 42.33143, "lon": -83.04575}}, {"facility": "GSK Investigational Site", "city": "Brooklyn Center", "state": "Minnesota", "zip": "55430", "country": "United States", "geoPoint": {"lat": 45.07608, "lon": -93.33273}}, {"facility": "GSK Investigational Site", "city": "Olive Branch", "state": "Mississippi", "zip": "38654", "country": "United States", "geoPoint": {"lat": 34.96176, "lon": -89.82953}}, {"facility": "GSK Investigational Site", "city": "Saint Louis", "state": "Missouri", "zip": "63141", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "GSK Investigational Site", "city": "Springfield", "state": "Missouri", "zip": "65807", "country": "United States", "geoPoint": {"lat": 37.21533, "lon": -93.29824}}, {"facility": "GSK Investigational Site", "city": "Omaha", "state": "Nebraska", "zip": "68134", "country": "United States", "geoPoint": {"lat": 41.25626, "lon": -95.94043}}, {"facility": "GSK Investigational Site", "city": "Omaha", "state": "Nebraska", "zip": "68144", "country": "United States", "geoPoint": {"lat": 41.25626, "lon": -95.94043}}, {"facility": "GSK Investigational Site", "city": "Henderson", "state": "Nevada", "zip": "89014", "country": "United States", "geoPoint": {"lat": 36.0397, "lon": -114.98194}}, {"facility": "GSK Investigational Site", "city": "Las Vegas", "state": "Nevada", "zip": "89119", "country": "United States", "geoPoint": {"lat": 36.17497, "lon": -115.13722}}, {"facility": "GSK Investigational Site", "city": "Las Vegas", "state": "Nevada", "zip": "89128", "country": "United States", "geoPoint": {"lat": 36.17497, "lon": -115.13722}}, {"facility": "GSK Investigational Site", "city": "Brick", "state": "New Jersey", "zip": "08724", "country": "United States", "geoPoint": {"lat": 40.05928, "lon": -74.13708}}, {"facility": "GSK Investigational Site", "city": "Elizabeth", "state": "New Jersey", "zip": "07202", "country": "United States", "geoPoint": {"lat": 40.66399, "lon": -74.2107}}, {"facility": "GSK Investigational Site", "city": "Albuquerque", "state": "New Mexico", "zip": "87102", "country": "United States", "geoPoint": {"lat": 35.08449, "lon": -106.65114}}, {"facility": "GSK Investigational Site", "city": "Albuquerque", "state": "New Mexico", "zip": "87108", "country": "United States", "geoPoint": {"lat": 35.08449, "lon": -106.65114}}, {"facility": "GSK Investigational Site", "city": "East Syracuse", "state": "New York", "zip": "13057", "country": "United States", "geoPoint": {"lat": 43.06534, "lon": -76.07853}}, {"facility": "GSK Investigational Site", "city": "Endwell", "state": "New York", "zip": "13760", "country": "United States", "geoPoint": {"lat": 42.11285, "lon": -76.02103}}, {"facility": "GSK Investigational Site", "city": "Fishkill", "state": "New York", "zip": "12524", "country": "United States", "geoPoint": {"lat": 41.53565, "lon": -73.89903}}, {"facility": "GSK Investigational Site", "city": "New York", "state": "New York", "zip": "10016", "country": "United States", "geoPoint": {"lat": 40.71427, "lon": -74.00597}}, {"facility": "GSK Investigational Site", "city": "New York", "state": "New York", "zip": "10021", "country": "United States", "geoPoint": {"lat": 40.71427, "lon": -74.00597}}, {"facility": "GSK Investigational Site", "city": "Charlotte", "state": "North Carolina", "zip": "28207", "country": "United States", "geoPoint": {"lat": 35.22709, "lon": -80.84313}}, {"facility": "GSK Investigational Site", "city": "Raleigh", "state": "North Carolina", "zip": "27612", "country": "United States", "geoPoint": {"lat": 35.7721, "lon": -78.63861}}, {"facility": "GSK Investigational Site", "city": "Statesville", "state": "North Carolina", "zip": "28625", "country": "United States", "geoPoint": {"lat": 35.78264, "lon": -80.8873}}, {"facility": "GSK Investigational Site", "city": "Wilmington", "state": "North Carolina", "zip": "28401", "country": "United States", "geoPoint": {"lat": 34.22573, "lon": -77.94471}}, {"facility": "GSK Investigational Site", "city": "Winston-Salem", "state": "North Carolina", "zip": "27103", "country": "United States", "geoPoint": {"lat": 36.09986, "lon": -80.24422}}, {"facility": "GSK Investigational Site", "city": "Cincinnati", "state": "Ohio", "zip": "45245", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "GSK Investigational Site", "city": "Cincinnati", "state": "Ohio", "zip": "45246", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "GSK Investigational Site", "city": "Cleveland", "state": "Ohio", "zip": "44195", "country": "United States", "geoPoint": {"lat": 41.4995, "lon": -81.69541}}, {"facility": "GSK Investigational Site", "city": "Kettering", "state": "Ohio", "zip": "45429", "country": "United States", "geoPoint": {"lat": 39.6895, "lon": -84.16883}}, {"facility": "GSK Investigational Site", "city": "Oklahoma City", "state": "Oklahoma", "zip": "73112", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "GSK Investigational Site", "city": "Erie", "state": "Pennsylvania", "zip": "16508", "country": "United States", "geoPoint": {"lat": 42.12922, "lon": -80.08506}}, {"facility": "GSK Investigational Site", "city": "Warminster", "state": "Pennsylvania", "zip": "18974", "country": "United States", "geoPoint": {"lat": 40.20678, "lon": -75.09962}}, {"facility": "GSK Investigational Site", "city": "West Chester", "state": "Pennsylvania", "zip": "19380", "country": "United States", "geoPoint": {"lat": 39.96097, "lon": -75.60804}}, {"facility": "GSK Investigational Site", "city": "Columbia", "state": "South Carolina", "zip": "29201", "country": "United States", "geoPoint": {"lat": 34.00071, "lon": -81.03481}}, {"facility": "GSK Investigational Site", "city": "Greer", "state": "South Carolina", "zip": "29651", "country": "United States", "geoPoint": {"lat": 34.93873, "lon": -82.22706}}, {"facility": "GSK Investigational Site", "city": "Hartsville", "state": "South Carolina", "zip": "29550", "country": "United States", "geoPoint": {"lat": 34.37404, "lon": -80.0734}}, {"facility": "GSK Investigational Site", "city": "Simpsonville", "state": "South Carolina", "zip": "29681", "country": "United States", "geoPoint": {"lat": 34.73706, "lon": -82.25428}}, {"facility": "GSK Investigational Site", "city": "Bristol", "state": "Tennessee", "zip": "37620", "country": "United States", "geoPoint": {"lat": 36.59511, "lon": -82.18874}}, {"facility": "GSK Investigational Site", "city": "Kingsport", "state": "Tennessee", "zip": "37660", "country": "United States", "geoPoint": {"lat": 36.54843, "lon": -82.56182}}, {"facility": "GSK Investigational Site", "city": "Corpus Christi", "state": "Texas", "zip": "78404", "country": "United States", "geoPoint": {"lat": 27.80058, "lon": -97.39638}}, {"facility": "GSK Investigational Site", "city": "San Antonio", "state": "Texas", "zip": "78237", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "GSK Investigational Site", "city": "San Antonio", "state": "Texas", "zip": "78258", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "GSK Investigational Site", "city": "Salt Lake City", "state": "Utah", "zip": "84109", "country": "United States", "geoPoint": {"lat": 40.76078, "lon": -111.89105}}, {"facility": "GSK Investigational Site", "city": "Burke", "state": "Virginia", "zip": "22015", "country": "United States", "geoPoint": {"lat": 38.79345, "lon": -77.27165}}, {"facility": "GSK Investigational Site", "city": "Galax", "state": "Virginia", "zip": "24333", "country": "United States", "geoPoint": {"lat": 36.66124, "lon": -80.92397}}, {"facility": "GSK Investigational Site", "city": "Manassas", "state": "Virginia", "zip": "22015", "country": "United States", "geoPoint": {"lat": 38.75095, "lon": -77.47527}}, {"facility": "GSK Investigational Site", "city": "Newport News", "state": "Virginia", "zip": "23606", "country": "United States", "geoPoint": {"lat": 37.08339, "lon": -76.46965}}, {"facility": "GSK Investigational Site", "city": "Richmond", "state": "Virginia", "zip": "23294", "country": "United States", "geoPoint": {"lat": 37.55376, "lon": -77.46026}}, {"facility": "GSK Investigational Site", "city": "Springfield", "state": "Virginia", "zip": "22151", "country": "United States", "geoPoint": {"lat": 38.78928, "lon": -77.1872}}, {"facility": "GSK Investigational Site", "city": "Virginia Beach", "state": "Virginia", "zip": "23451", "country": "United States", "geoPoint": {"lat": 36.85293, "lon": -75.97799}}, {"facility": "GSK Investigational Site", "city": "Walla Walla", "state": "Washington", "zip": "99362", "country": "United States", "geoPoint": {"lat": 46.06458, "lon": -118.34302}}, {"facility": "GSK Investigational Site", "city": "Lewisburg", "state": "West Virginia", "zip": "24901", "country": "United States", "geoPoint": {"lat": 37.80179, "lon": -80.44563}}, {"facility": "GSK Investigational Site", "city": "Calgary", "state": "Alberta", "zip": "T2E 7C5", "country": "Canada", "geoPoint": {"lat": 51.05011, "lon": -114.08529}}, {"facility": "GSK Investigational Site", "city": "Calgary", "state": "Alberta", "zip": "T3C 3P1", "country": "Canada", "geoPoint": {"lat": 51.05011, "lon": -114.08529}}, {"facility": "GSK Investigational Site", "city": "Edmonton", "state": "Alberta", "zip": "T5A 4L8", "country": "Canada", "geoPoint": {"lat": 53.55014, "lon": -113.46871}}, {"facility": "GSK Investigational Site", "city": "St. John's", "state": "Newfoundland and Labrador", "zip": "A1E 2E2", "country": "Canada", "geoPoint": {"lat": 47.56494, "lon": -52.70931}}, {"facility": "GSK Investigational Site", "city": "Truro", "state": "Nova Scotia", "zip": "B2N 1L2", "country": "Canada", "geoPoint": {"lat": 45.36685, "lon": -63.26538}}, {"facility": "GSK Investigational Site", "city": "Brampton", "state": "Ontario", "zip": "L6T 3T1", "country": "Canada", "geoPoint": {"lat": 43.68341, "lon": -79.76633}}, {"facility": "GSK Investigational Site", "city": "London", "state": "Ontario", "zip": "N5W 6A2", "country": "Canada", "geoPoint": {"lat": 42.98339, "lon": -81.23304}}, {"facility": "GSK Investigational Site", "city": "Newmarket", "state": "Ontario", "zip": "L3Y 5G8", "country": "Canada", "geoPoint": {"lat": 44.05011, "lon": -79.46631}}, {"facility": "GSK Investigational Site", "city": "Peterborough", "state": "Ontario", "zip": "K9J 7B3", "country": "Canada", "geoPoint": {"lat": 44.30012, "lon": -78.31623}}, {"facility": "GSK Investigational Site", "city": "Sarnia", "state": "Ontario", "zip": "N7T 4X3", "country": "Canada", "geoPoint": {"lat": 42.97866, "lon": -82.40407}}, {"facility": "GSK Investigational Site", "city": "Sudbury", "state": "Ontario", "zip": "P3C 5K7", "country": "Canada", "geoPoint": {"lat": 46.49, "lon": -80.99001}}, {"facility": "GSK Investigational Site", "city": "Sudbury", "state": "Ontario", "zip": "P3E 1H5", "country": "Canada", "geoPoint": {"lat": 46.49, "lon": -80.99001}}, {"facility": "GSK Investigational Site", "city": "Gatineau", "state": "Quebec", "zip": "J8Y 6S8", "country": "Canada", "geoPoint": {"lat": 45.47723, "lon": -75.70164}}, {"facility": "GSK Investigational Site", "city": "Mirabel", "state": "Quebec", "zip": "J7J 2K8", "country": "Canada", "geoPoint": {"lat": 45.65008, "lon": -74.08251}}, {"facility": "GSK Investigational Site", "city": "Trois Rivieres", "state": "Quebec", "zip": "G8T 7A1", "country": "Canada", "geoPoint": {"lat": 46.34515, "lon": -72.5477}}, {"facility": "GSK Investigational Site", "city": "Ponce", "zip": "731", "country": "Puerto Rico", "geoPoint": {"lat": 18.01108, "lon": -66.61406}}, {"facility": "GSK Investigational Site", "city": "Rio Grande", "zip": "00745", "country": "Puerto Rico", "geoPoint": {"lat": 18.38023, "lon": -65.83127}}, {"facility": "GSK Investigational Site", "city": "Rio Piedras", "zip": "00935", "country": "Puerto Rico", "geoPoint": {"lat": 18.39745, "lon": -66.04989}}]}, "referencesModule": {"seeAlsoLinks": [{"label": "Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.", "url": "https://www.clinicalstudydatarequest.com"}], "availIpds": [{"id": "COR103561", "type": "Statistical Analysis Plan", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "COR103561", "type": "Clinical Study Report", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "COR103561", "type": "Individual Participant Data Set", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "COR103561", "type": "Annotated Case Report Form", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "COR103561", "type": "Dataset Specification", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "COR103561", "type": "Informed Consent Form", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "COR103561", "type": "Study Protocol", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site."}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Coreg CR", "description": "Carvedilol Phosphate Extended Release 20 mg, 40 mg, and 80 mg Capsules QD (once daily)"}, {"id": "FG001", "title": "Toprol XL", "description": "Metoprolol Succinate Extended Release 50 mg, 100 mg, and 200 mg Tablets QD (once daily)"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "290"}, {"groupId": "FG001", "numSubjects": "278"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "221"}, {"groupId": "FG001", "numSubjects": "190"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "69"}, {"groupId": "FG001", "numSubjects": "88"}]}], "dropWithdraws": [{"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "16"}, {"groupId": "FG001", "numSubjects": "19"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "21"}, {"groupId": "FG001", "numSubjects": "19"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "14"}, {"groupId": "FG001", "numSubjects": "18"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "25"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "4"}]}, {"type": "Non-Compliance", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Other", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Worsening serum lipid levels", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Coreg CR", "description": "Carvedilol Phosphate Extended Release 20 mg, 40 mg, and 80 mg Capsules QD (once daily)"}, {"id": "BG001", "title": "Toprol XL", "description": "Metoprolol Succinate Extended Release 50 mg, 100 mg, and 200 mg Tablets QD (once daily)"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "290"}, {"groupId": "BG001", "value": "278"}, {"groupId": "BG002", "value": "568"}]}], "measures": [{"title": "Age, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "< 65 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "260"}, {"groupId": "BG001", "value": "244"}, {"groupId": "BG002", "value": "504"}]}]}, {"title": ">=65 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "30"}, {"groupId": "BG001", "value": "34"}, {"groupId": "BG002", "value": "64"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "137"}, {"groupId": "BG001", "value": "133"}, {"groupId": "BG002", "value": "270"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "153"}, {"groupId": "BG001", "value": "145"}, {"groupId": "BG002", "value": "298"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Black", "categories": [{"measurements": [{"groupId": "BG000", "value": "24"}, {"groupId": "BG001", "value": "28"}, {"groupId": "BG002", "value": "52"}]}]}, {"title": "White/Caucasian", "categories": [{"measurements": [{"groupId": "BG000", "value": "239"}, {"groupId": "BG001", "value": "226"}, {"groupId": "BG002", "value": "465"}]}]}, {"title": "Other", "categories": [{"measurements": [{"groupId": "BG000", "value": "27"}, {"groupId": "BG001", "value": "24"}, {"groupId": "BG002", "value": "51"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Triglycerides Levels by Treatment Group at Maintenance Month 6", "description": "Blood draw for triglyceride levels. Full beta quantification test performed which uses ultracentrifugation to partially separate lipoprotein classes and is the basis for the reference methods. Change = Month 6 value minus Baseline value.", "populationDescription": "The Intent to Treat (ITT-E) Population was used for analysis of the efficacy results and consisted of all subjects who randomized, received at least one dose of study medication, and had both a baseline and at least one on-therapy value for an efficacy parameter during the maintenance phase(number of participants will vary between measures).", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Month 6", "groups": [{"id": "OG000", "title": "Coreg CR", "description": "Carvedilol Phosphate Extended Release 20 mg, 40 mg, and 80 mg Capsules QD (once daily)"}, {"id": "OG001", "title": "Toprol XL", "description": "Metoprolol Succinate Extended Release 50 mg, 100 mg, and 200 mg Tablets QD (once daily)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "235"}, {"groupId": "OG001", "value": "206"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.65"}, {"groupId": "OG001", "value": "10.39"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0141", "statisticalMethod": "ANCOVA", "paramType": "Median Difference (Net)", "paramValue": "-8.026", "ciPctValue": "95", "ciLowerLimit": "-15.35", "ciUpperLimit": "-0.67", "estimateComment": "Median difference = Coreg CR - Toprol XL"}]}, {"type": "PRIMARY", "title": "Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) Levels by Treatment Group at Maintenance Month 6", "description": "Blood draw for HDL-C levels. Full beta Quant test performed with HDL subclasses. Change = Month 6 value minus Baseline value.", "populationDescription": "The Intent to Treat (ITT-E) Population was used for analysis of the efficacy results and consisted of all subjects who randomized, received at least one dose of study medication, and had both a baseline and at least one on-therapy value for an efficacy parameter during the maintenance phase(number of participants will vary between measures).", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Month 6", "groups": [{"id": "OG000", "title": "Coreg CR", "description": "Carvedilol Phosphate Extended Release 20 mg, 40 mg, and 80 mg Capsules QD (once daily)"}, {"id": "OG001", "title": "Toprol XL", "description": "Metoprolol Succinate Extended Release 50 mg, 100 mg, and 200 mg Tablets QD (once daily)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "235"}, {"groupId": "OG001", "value": "206"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-4.4"}, {"groupId": "OG001", "value": "-5.1"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.6068", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Net)", "paramValue": "0.7", "ciPctValue": "95", "ciLowerLimit": "-2.4", "ciUpperLimit": "3.9", "estimateComment": "Mean difference = Coreg CR - Toprol XL"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Log Transformed High Sensitivity C-reactive Protein (Hs-CRP) by Treatment Group at Maintenance Month 6", "description": "Blood draw for hs-CRP. Change = Month 6 value minus Baseline value.", "populationDescription": "The Intent to Treat (ITT-E) Population was used for analysis of the efficacy results and consisted of all subjects who randomized, received at least one dose of study medication, and had both a baseline and at least one on-therapy value for an efficacy parameter during the maintenance phase(number of participants will vary between measures).", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Month 6", "groups": [{"id": "OG000", "title": "Coreg CR", "description": "Carvedilol Phosphate Extended Release 20 mg, 40 mg, and 80 mg Capsules QD (once daily)"}, {"id": "OG001", "title": "Toprol XL", "description": "Metoprolol Succinate Extended Release 50 mg, 100 mg, and 200 mg Tablets QD (once daily)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "231"}, {"groupId": "OG001", "value": "203"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.76"}, {"groupId": "OG001", "value": "0.49"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Log Transformed Lipoprotein-associated Phospholipase A2 (LpPLA2) by Treatment Group at Maintenance Month 6", "description": "Blood draw for LpPLA2 activity. Change = Month 6 value minus Baseline value.", "populationDescription": "The Intent to Treat (ITT-E) Population was used for analysis of the efficacy results and consisted of all subjects who randomized, received at least one dose of study medication, and had both a baseline and at least one on-therapy value for an efficacy parameter during the maintenance phase(number of participants will vary between measures).", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "mcmol/min/L", "timeFrame": "Baseline and Month 6", "groups": [{"id": "OG000", "title": "Coreg CR", "description": "Carvedilol Phosphate Extended Release 20 mg, 40 mg, and 80 mg Capsules QD (once daily)"}, {"id": "OG001", "title": "Toprol XL", "description": "Metoprolol Succinate Extended Release 50 mg, 100 mg, and 200 mg Tablets QD (once daily)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "222"}, {"groupId": "OG001", "value": "189"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-2.38"}, {"groupId": "OG001", "value": "-2.23"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Blood Pressure by Treatment Group at Maintenance Month 6", "description": "Manual physical examination (cuff blood pressure). Change = Month 6 value minus Baseline value.", "populationDescription": "The Intent to Treat (ITT-E) Population was used for analysis of the efficacy results and consisted of all subjects who randomized, received at least one dose of study medication, and had both a baseline and at least one on-therapy value for an efficacy parameter during the maintenance phase(number of participants will vary between measures).", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline and Month 6", "groups": [{"id": "OG000", "title": "Coreg CR", "description": "Carvedilol Phosphate Extended Release 20 mg, 40 mg, and 80 mg Capsules QD (once daily)"}, {"id": "OG001", "title": "Toprol XL", "description": "Metoprolol Succinate Extended Release 50 mg, 100 mg, and 200 mg Tablets QD (once daily)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "280"}, {"groupId": "OG001", "value": "269"}]}], "classes": [{"title": "Systolic Blood Pressure", "categories": [{"measurements": [{"groupId": "OG000", "value": "-15.90"}, {"groupId": "OG001", "value": "-16.23"}]}]}, {"title": "Diastolic Blood Pressure", "categories": [{"measurements": [{"groupId": "OG000", "value": "-10.89"}, {"groupId": "OG001", "value": "-11.06"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Heart Rate by Treatment Group at Maintenance Month 6", "description": "Manual physical examination. Change = Month 6 value minus Baseline value. (BPM=beats per minute)", "populationDescription": "The Intent to Treat (ITT-E) Population was used for analysis of the efficacy results and consisted of all subjects who randomized, received at least one dose of study medication, and had both a baseline and at least one on-therapy value for an efficacy parameter during the maintenance phase(number of participants will vary between measures).", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "bpm", "timeFrame": "Baseline and Month 6", "groups": [{"id": "OG000", "title": "Coreg CR", "description": "Carvedilol Phosphate Extended Release 20 mg, 40 mg, and 80 mg Capsules QD (once daily)"}, {"id": "OG001", "title": "Toprol XL", "description": "Metoprolol Succinate Extended Release 50 mg, 100 mg, and 200 mg Tablets QD (once daily)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "280"}, {"groupId": "OG001", "value": "269"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-5.98"}, {"groupId": "OG001", "value": "-6.07"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Weight by Treatment Group at Maintenance Month", "description": "Manual physical examination. Change = Month 6 value minus Baseline value.", "populationDescription": "The Intent to Treat (ITT-E) Population was used for analysis of the efficacy results and consisted of all subjects who randomized, received at least one dose of study medication, and had both a baseline and at least one on-therapy value for an efficacy parameter during the maintenance phase(number of participants will vary between measures).", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "kg", "timeFrame": "Baseline and Month 6", "groups": [{"id": "OG000", "title": "Coreg CR", "description": "Carvedilol Phosphate Extended Release 20 mg, 40 mg, and 80 mg Capsules QD (once daily)"}, {"id": "OG001", "title": "Toprol XL", "description": "Metoprolol Succinate Extended Release 50 mg, 100 mg, and 200 mg Tablets QD (once daily)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "280"}, {"groupId": "OG001", "value": "269"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.01"}, {"groupId": "OG001", "value": "0.73"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Additional Lipid Parameters by Treatment Group With Unit of Measures of mg/dL at Maintenance Month 6", "description": "Blood draw for lipid levels. Full beta Quant test performed with HDL subclasses and IDL. IDL=Intermediate density lipoproteins, LDL=Low-density lipoprotein, VLDL=Very Low density lipoprotein, HDL=High-density lipoprotein. Change = Month 6 value minus Baseline value.", "populationDescription": "The Intent to Treat (ITT-E) Population was used for analysis of the efficacy results and consisted of all subjects who randomized, received at least one dose of study medication, and had both a baseline and at least one on-therapy value for an efficacy parameter during the maintenance phase(number of participants will vary between measures).", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Month 6", "groups": [{"id": "OG000", "title": "Coreg CR", "description": "Carvedilol Phosphate Extended Release 20 mg, 40 mg, and 80 mg Capsules QD (once daily)"}, {"id": "OG001", "title": "Toprol XL", "description": "Metoprolol Succinate Extended Release 50 mg, 100 mg, and 200 mg Tablets QD (once daily)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "280"}, {"groupId": "OG001", "value": "269"}]}], "classes": [{"title": "Total Serum Cholesterol", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.1"}, {"groupId": "OG001", "value": "-0.7"}]}]}, {"title": "Low-Density Lipoprotein (LDL)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.1"}, {"groupId": "OG001", "value": "-1.7"}]}]}, {"title": "Low+Very Low Density Lipoprotein", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.9"}, {"groupId": "OG001", "value": "0.4"}]}]}, {"title": "High-Density Lipoprotein 2 (HDL2)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.45"}, {"groupId": "OG001", "value": "-6.5"}]}]}, {"title": "High-Density Lipoprotein 3 (HDL3)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-4.0"}, {"groupId": "OG001", "value": "-3.5"}]}]}, {"title": "Low-Density Lipoprotein-Relative Flotation", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.166"}, {"groupId": "OG001", "value": "-1.360"}]}]}, {"title": "Intermediate Density Lipoproteins+VLDL", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.0"}, {"groupId": "OG001", "value": "5.6"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Additional Lipid Parameters by Treatment Group With Unit of Measures of g/L at Maintenance Month 6", "description": "Blood draw for lipid levels. Full beta Quant test performed. Change = Month 6 value minus Baseline value.", "populationDescription": "The Intent to Treat (ITT-E) Population was used for analysis of the efficacy results and consisted of all subjects who randomized, received at least one dose of study medication, and had both a baseline and at least one on-therapy value for an efficacy parameter during the maintenance phase(number of participants will vary between measures).", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "g/L", "timeFrame": "Baseline and Month 6", "groups": [{"id": "OG000", "title": "Coreg CR", "description": "Carvedilol Phosphate Extended Release 20 mg, 40 mg, and 80 mg Capsules QD (once daily)"}, {"id": "OG001", "title": "Toprol XL", "description": "Metoprolol Succinate Extended Release 50 mg, 100 mg, and 200 mg Tablets QD (once daily)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "280"}, {"groupId": "OG001", "value": "269"}]}], "classes": [{"title": "Apolipoprotein A-1 (Apo-A1)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.82"}, {"groupId": "OG001", "value": "-3.45"}]}]}, {"title": "Apolipoprotein B (Apo-B)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.16"}, {"groupId": "OG001", "value": "0.81"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Insulin (Glycemic Parameter) by Treatment Group at Maintenance Month 6", "description": "Blood draw for glycemia levels. Full beta Quant test performed. Test for Fasting plasma glucose, HbA1c, fasting insulin. Homeostasis model Assessment (HOMA) is a computer-generated model consisting of non-linear empirical equations solved numerically to predict glucose, Insulin and C-peptide concentrations in fasting subjects for insulin sensitivity (%S). Change = Month 6 value minus Baseline value.", "populationDescription": "The Intent to Treat (ITT-E) Population was used for analysis of the efficacy results and consisted of all subjects who randomized, received at least one dose of study medication, and had both a baseline and at least one on-therapy value for an efficacy parameter during the maintenance phase(number of participants will vary between measures).", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "uIU/mL", "timeFrame": "Baseline and Month 6", "groups": [{"id": "OG000", "title": "Coreg CR", "description": "Carvedilol Phosphate Extended Release 20 mg, 40 mg, and 80 mg Capsules QD (once daily)"}, {"id": "OG001", "title": "Toprol XL", "description": "Metoprolol Succinate Extended Release 50 mg, 100 mg, and 200 mg Tablets QD (once daily)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "280"}, {"groupId": "OG001", "value": "269"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.21"}, {"groupId": "OG001", "value": "1.35"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Hemoglobin A1c (HbA1c) (Glycemic Parameter) by Treatment Group at Maintenance Month 6", "description": "Blood draw for glycemia levels. Full beta Quant test performed. Test for Fasting plasma glucose, HbA1c, fasting insulin. Homeostasis model Assessment (HOMA) is a computer-generated model consisting of non-linear empirical equations solved numerically to predict glucose, Insulin and C-peptide concentrations in fasting subjects for insulin sensitivity (%S). Change = Month 6 value minus Baseline value.", "populationDescription": "The Intent to Treat (ITT-E) Population was used for analysis of the efficacy results and consisted of all subjects who randomized, received at least one dose of study medication, and had both a baseline and at least one on-therapy value for an efficacy parameter during the maintenance phase(number of participants will vary between measures).", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percent Change", "timeFrame": "Baseline and Month 6", "groups": [{"id": "OG000", "title": "Coreg CR", "description": "Carvedilol Phosphate Extended Release 20 mg, 40 mg, and 80 mg Capsules QD (once daily)"}, {"id": "OG001", "title": "Toprol XL", "description": "Metoprolol Succinate Extended Release 50 mg, 100 mg, and 200 mg Tablets QD (once daily)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "280"}, {"groupId": "OG001", "value": "269"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.01"}, {"groupId": "OG001", "value": "0.04"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in c-Peptide (Glycemic Parameter) by Treatment Group at Maintenance Month 6", "description": "Blood draw for glycemia levels. Full beta Quant test performed. Test for Fasting plasma glucose, HbA1c, fasting insulin. Homeostasis model Assessment (HOMA) is a computer-generated model consisting of non-linear empirical equations solved numerically to predict glucose, Insulin and C-peptide concentrations in fasting subjects for insulin sensitivity (%S). Change = Month 6 value minus Baseline value.", "populationDescription": "The Intent to Treat (ITT-E) Population was used for analysis of the efficacy results and consisted of all subjects who randomized, received at least one dose of study medication, and had both a baseline and at least one on-therapy value for an efficacy parameter during the maintenance phase(number of participants will vary between measures).", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "ng/mL", "timeFrame": "Baseline and Month 6", "groups": [{"id": "OG000", "title": "Coreg CR", "description": "Carvedilol Phosphate Extended Release 20 mg, 40 mg, and 80 mg Capsules QD (once daily)"}, {"id": "OG001", "title": "Toprol XL", "description": "Metoprolol Succinate Extended Release 50 mg, 100 mg, and 200 mg Tablets QD (once daily)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "280"}, {"groupId": "OG001", "value": "269"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.23"}, {"groupId": "OG001", "value": "0.20"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Homeostasis Model Assessment (Glycemic Parameter) by Treatment Group at Maintenance Month 6", "description": "Blood draw for glycemia levels. Full beta Quant test performed. Test for Fasting plasma glucose, HbA1c, fasting insulin. Homeostasis model Assessment (HOMA) is a computer-generated model consisting of non-linear empirical equations solved numerically to predict glucose, Insulin and C-peptide concentrations in fasting subjects for insulin sensitivity (%S). Change = Month 6 value minus Baseline value.", "populationDescription": "The Intent to Treat (ITT-E) Population was used for analysis of the efficacy results and consisted of all subjects who randomized, received at least one dose of study medication, and had both a baseline and at least one on-therapy value for an efficacy parameter during the maintenance phase(number of participants will vary between measures).", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percent Change", "timeFrame": "Baseline and Month 6", "groups": [{"id": "OG000", "title": "Coreg CR", "description": "Carvedilol Phosphate Extended Release 20 mg, 40 mg, and 80 mg Capsules QD (once daily)"}, {"id": "OG001", "title": "Toprol XL", "description": "Metoprolol Succinate Extended Release 50 mg, 100 mg, and 200 mg Tablets QD (once daily)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "280"}, {"groupId": "OG001", "value": "269"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.05"}, {"groupId": "OG001", "value": "-4.14"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Plasma Glucose (FPG) (Glycemic Parameter) by Treatment Group at Maintenance Month 6", "description": "Blood draw for glycemia levels. Full beta Quant test performed. Test for Fasting plasma glucose, HbA1c, fasting insulin. Homeostasis model Assessment (HOMA) is a computer-generated model consisting of non-linear empirical equations solved numerically to predict glucose, Insulin and C-peptide concentrations in fasting subjects for insulin sensitivity (%S). Change = Month 6 value minus Baseline value.", "populationDescription": "The Intent to Treat (ITT-E) Population was used for analysis of the efficacy results and consisted of all subjects who randomized, received at least one dose of study medication, and had both a baseline and at least one on-therapy value for an efficacy parameter during the maintenance phase(number of participants will vary between measures).", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Month 6", "groups": [{"id": "OG000", "title": "Coreg CR", "description": "Carvedilol Phosphate Extended Release 20 mg, 40 mg, and 80 mg Capsules QD (once daily)"}, {"id": "OG001", "title": "Toprol XL", "description": "Metoprolol Succinate Extended Release 50 mg, 100 mg, and 200 mg Tablets QD (once daily)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "280"}, {"groupId": "OG001", "value": "269"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.94"}, {"groupId": "OG001", "value": "1.20"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Coreg CR", "description": "Results include only treatment emergent events.", "seriousNumAffected": 8, "otherNumAffected": 186}, {"id": "EG001", "title": "Toprol XL", "description": "Results include only treatment emergent events.", "seriousNumAffected": 5, "otherNumAffected": 160}], "seriousEvents": [{"term": "Breast cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 290}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 278}]}, {"term": "Chest discomfort", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 290}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 278}]}, {"term": "Colitis ischaemic", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 290}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 278}]}, {"term": "Depression suicidal", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 290}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 278}]}, {"term": "Gastroesophagael reflux disease", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 290}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 278}]}, {"term": "Hydronephrosis", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 290}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 278}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 290}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 278}]}, {"term": "Myocardial Infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 290}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 278}]}, {"term": "Orthostatic hypotension", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 290}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 278}]}, {"term": "Palpitations", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 290}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 278}]}, {"term": "Peridiverticular abscess", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 290}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 278}]}, {"term": "Presyncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 290}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 278}]}, {"term": "Umbilical hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 290}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 278}]}], "otherEvents": [{"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 42, "numAtRisk": 290}, {"groupId": "EG001", "numAffected": 33, "numAtRisk": 278}]}, {"term": "Edema Peripheral", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 29, "numAtRisk": 290}, {"groupId": "EG001", "numAffected": 25, "numAtRisk": 278}]}, {"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 22, "numAtRisk": 290}, {"groupId": "EG001", "numAffected": 29, "numAtRisk": 278}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 28, "numAtRisk": 290}, {"groupId": "EG001", "numAffected": 18, "numAtRisk": 278}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 16, "numAtRisk": 290}, {"groupId": "EG001", "numAffected": 17, "numAtRisk": 278}]}, {"term": "Upper Respiratory Tract Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 19, "numAtRisk": 290}, {"groupId": "EG001", "numAffected": 12, "numAtRisk": 278}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 18, "numAtRisk": 290}, {"groupId": "EG001", "numAffected": 11, "numAtRisk": 278}]}, {"term": "Diarrhea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 12, "numAtRisk": 290}, {"groupId": "EG001", "numAffected": 15, "numAtRisk": 278}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centres of a multi-centre trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."}, "pointOfContact": {"title": "GSK Response Center", "organization": "GlaxoSmithKline", "phone": "866-435-7343"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-26"}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008790", "term": "Metoprolol"}, {"id": "D000077261", "term": "Carvedilol"}], "ancestors": [{"id": "D000000889", "term": "Anti-Arrhythmia Agents"}, {"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000013565", "term": "Sympatholytics"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000058671", "term": "Adrenergic beta-1 Receptor Antagonists"}, {"id": "D000000319", "term": "Adrenergic beta-Antagonists"}, {"id": "D000018674", "term": "Adrenergic Antagonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000000975", "term": "Antioxidants"}, {"id": "D000020011", "term": "Protective Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000058668", "term": "Adrenergic alpha-1 Receptor Antagonists"}, {"id": "D000000317", "term": "Adrenergic alpha-Antagonists"}], "browseLeaves": [{"id": "M1718", "name": "Carvedilol", "asFound": "Depressive Disorder", "relevance": "HIGH"}, {"id": "M11762", "name": "Metoprolol", "asFound": "HDL", "relevance": "HIGH"}, {"id": "M4213", "name": "Anti-Arrhythmia Agents", "relevance": "LOW"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M16344", "name": "Sympatholytics", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M29197", "name": "Adrenergic beta-1 Receptor Antagonists", "relevance": "LOW"}, {"id": "M3671", "name": "Adrenergic beta-Antagonists", "relevance": "LOW"}, {"id": "M20755", "name": "Adrenergic Antagonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}, {"id": "M4292", "name": "Antioxidants", "relevance": "LOW"}, {"id": "M21869", "name": "Protective Agents", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M29194", "name": "Adrenergic alpha-1 Receptor Antagonists", "relevance": "LOW"}, {"id": "M3669", "name": "Adrenergic alpha-Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AnArAg", "name": "Anti-Arrhythmia Agents"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}]}}, "hasResults": true}